HEDROS Engages ANPLAC's Shrimp Hatchery Producers in Mazatlán as Part of the Pre-Launch Activities for the Anti Vibrio Solution, FAGOX TM; The Dialogue Brings HEDROSa Step Closer to Delivering Phage

The HEDROS team traveled to Mazatlán, Sinaloa, to communicate the value proposition of

o

ur anti-vibrio solution, FAGOX TM, set to launch in Mexico in 2025. To that end, we

sought to listen, and connect with hatchery personnel who face the daily challenges of

larval production. We also sought to educate producers as part of our continous dialogue

on the beneficial use of bacteriophages in Mexican aquaculture. This visit marks a key step

in our mission to build a healthier, more sustainable industry—one free of pathogenic

bacteria.

HEDROS' technology team carried out field trials and technical consultations with shrimp

hatcheries in El Caimanero to validate the performance of FAGOX in commercial settings.

Additionally, the marketing team hosted a Lunch and Learn session, co-organized by

ANPLAC, that was attended by Mexico's top hatcheries. HEDROS presented efficacy data,

details on the technology mode of action, as well as on farm application protocols. The

event was also successful in obtaining voice of customer and feedback on the pre-launch

activities.

ANPLAC members found the engagement very useful and left with gifts, a technical

package and, above all, a deep conviction that phages are part of the future of aquatic

animal health.

ANPLAC Participation

We were joined and supported by the National Association of Shrimp Larvae Producers

(ANPLAC), who facilitated key contacts and helped coordinate the meeting. Their

participation was essential in opening technical conversations and sparking genuine

interest in solutions that prioritize prevention and healthy farming practices.

Next Steps

The challenges facing Mexican aquaculture remain significant. The sector continues to face

complex environmental conditions—such as temperature fluctuations, declining water

quality, and overstocking in culture systems—that increase the risk of pathogenic vibrios

and antimicrobial resistance. There is still a reliance on traditional, but undesirable

solutions such as antibiotics, which means that building trust in biological alternatives like

phages will take time, measurable results, and ongoing communication efforts. HEDROS is

collaborating with Mexico's regulatory agencies and working closely with industry groups,

like ANPLAC, to effectively communicate the benefits of bacteriophages and pioneer the

introduction of sustainable antimicrobial solutions, such as FAGOX. HEDROS will continue

its Responsible Phage program to ensure proper understanding and adoption of this

game-changing technology.